AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01938313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional perioperative cares
Description: 1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Routine drain insertion~12. Levin tube insertion if needed
Study NCT03040609 — intervention group
Intervention type: BEHAVIORAL
Intervention: Visual-behavioral Scale at day 1
Description: To perform the classification with the scale by caregiver.
Study NCT03040609 — intervention group
Intervention type: BEHAVIORAL
Intervention: Test-retest at the end of 2 weeks
Description: To perform the classification with the scale by orthoptist at the end of 2 weeks
Study NCT03040609 — intervention group
Intervention type: BEHAVIORAL
Intervention: Test at 6 months
Description: To perform the classification with the scale by orthoptist at the end 6 months.
Study NCT00632021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease
Description: Before hospital discharge, a pharmacist will provide medication reconciliation and counseling on how to take medications. Participants will receive a follow-up phone call 1 to 4 days after hospital discharge to discuss any medication problems, and additionally as needed.
Study NCT02000128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bioimpedance monitoring
Description: To assess the body composition using Multi-frequency bioelectrical impedance analysis
Study NCT02000128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: clinical monitoring
Description: clinical symptom and examination,such as edema, body weight, blood pressure, cardial function
Study NCT02640105 — intervention group
Intervention type: OTHER
Intervention: Neurological clinical examination
Description: Diagnostic and description of cluster headache
Study NCT02640105 — intervention group
Intervention type: OTHER
Intervention: Psychological clinical examination
Description: Scale and questionnaires
Study NCT02640105 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Psychopathological and cognitive questionnaires
Study NCT02640105 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample for DNA collection
Study NCT02640105 — intervention group
Intervention type: OTHER
Intervention: Endothelial function measurement
Description: Endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
Study NCT02008071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily step goal financial incentive
Description: Participants' daily activity was incentivized. Reaching a predetermined/individualized step goal each day resulted in 1.00 per day.
Study NCT02008071 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard payment of 70.00 at the beginning of the study. Participants' daily activity was not incentivized.
Study NCT01424462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: Single dose treatment IR formulation
Study NCT01424462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B
Description: Low Extended release single dose
Study NCT01424462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C
Description: Medium extended release formulation
Study NCT01424462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D
Description: High extended release rate single dose
Study NCT03197025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg (based on total body weight) intravenous (IV) infused over 15 minutes approximately every 12 hours for a maximum of two doses.
Study NCT03197025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E6 T Cell Receptor (TCR)
Description: On day 0, the E6 TCR cells will be administered one time, intravenously over 20 to 30 minutes
Study NCT02643628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling
Study NCT02643628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedling followed by Bellafill treatment
Study NCT01617499 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physical activity
Description: The worksite wellness program included cardiovascular health assessments, personal health reports, 8 weeks of pedometer-based walking and tracking activities, and weekly wellness sessions.
Study NCT03959852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1 mg/kg of Fentanyl IV administered over at least 1 minute
Study NCT03959852 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fentanyl and Ketamine
Description: Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute.
Study NCT03959852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
Study NCT00227123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine, risperidone
Description: Flexible dose titrations to 'treat-to-symptoms'
Study NCT04430803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water
Description: A tablet that produces hydrogen dissolved in a glass of water
Study NCT04430803 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Water
Description: A glass of tap water
Study NCT03297476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: High-risk subtype detection panels
Description: The designed detection technology were used to identify the high-risk patients cohort.
Study NCT02839785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
Study NCT02839785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
Study NCT02880839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Partial cervical lamina excision group
Description: Patients with cervical fracture were assigned to undergo partial cervical lamina excision and cervical pedicle screw internal fixation.
Study NCT02880839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipeline-dredge discharge group
Description: Patients with cervical fracture were assigned to undergo pipeline-dredge discharge and cervical pedicle screw internal fixation.
Study NCT02880839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital navigation group
Description: Patients with cervical fracture were assigned to undergo digital navigation assisted cervical pedicle screw placement.
Study NCT00718471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: ENOXAPARIN IV 0.5 mg.kg
Study NCT00718471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFH (unfractionated heparin)
Description: UFH IV 50-70 IU if GP IIbIIIa or 70-100IU if no GP IIbIIIa
Study NCT04041830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit 1
Description: the participants will fill in the LFPQ questionnaire before and after a lunch test meal
Study NCT04041830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit 2
Description: this is a replication of Visit 1, testing the reproducibility of the LFPQ and of its response to a meal.
Study NCT03577314 — intervention group
Intervention type: OTHER
Intervention: miscarriage
Description: (ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
Study NCT02318654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice Pack
Description: Subjects will have 600 grams of ice in clear plastic bag size 18 x 23 cm applied to the randomized axilla for 10 minutes. After 10 minutes, the ice pack will be removed and laser hair treatment will be performed.
Study NCT02318654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical EMLA cream
Description: Topical EMLA will be applied approximately 2 mm thick to the randomized axilla with a wooden tongue depressor wrapped with impermeable plastic occlusion dressing for 60 minutes. After 60 minutes, the drug will be removed with regular gauze and saline and laser hair treatment will be performed.
Study NCT03051347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Itch Questionnaire and Interview
Study NCT03051347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stigma Questionnaire and Interview
Study NCT03051347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive Interview and PROMIS Itch Questionnaire
Study NCT04122625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143
Description: Administered as capsules.
Study NCT04122625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered as IV infusion.
Study NCT03425994 — intervention group
Intervention type: DRUG
Intervention: Elvitegravir/Cobicistat/Emtricitabine
Description: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 150mg/150mg/200mg/10mg (Genvoya) film coated tablet
Study NCT01684124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative O2 therapy
Description: target lower O2 saturation
Study NCT01684124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard care
Study NCT03852498 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Lenti-D
Description: Participants received a single IV infusion of Lenti-D Drug Product.
Study NCT03402425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FET PET
Description: Patient are investigated with an 18F-FET PET
Study NCT06012526 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Polysomnography is done for patients to find any sleep disordered breathing
Study NCT00415324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study NCT00415324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00415324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative study
Study NCT00415324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative study
Study NCT03514056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: group 1:Patients diagnosed with Behcet disease
Description: Frequency and severity of fibromyalgia will be investigated in patient diagnosed with Behcet disease
Study NCT03514056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: group 2: Patient diagnosed with fibromyalgia without Behcet disease
Description: Severity of fibromyalgia will be investigated in patient diagnosed with fibromyalgia
Study NCT03637309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BeReady2Smile Video and App
Description: BeReady2Smile is a coordinated oral health prevention intervention program that includes video content that features demonstrations/content on encouraging brushing, proper loading of toothbrush, brushing duration and frequency, fluoride myths, and limiting sugar sweetened beverages and milk in baby bottles while in bed. BeReady2Smile will also include a mobile application built within a web-based infrastructure, so parents can participate in multi-media educational activities, develop dental health behavior plans, tailor features and receive feedback from the system on a secure website.
Study NCT03072823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 Polyunsaturated fatty acid
Description: 2 g of Eicosapentaenoic acid (EPA) and 1 g of Docosahexaenoic acid (DHA)
Study NCT03072823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: olive oil ethyl esters
Study NCT00786643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU bolus was administered at 400mg/m\^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m\^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.
Study NCT00786643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV)
Description: Leucovorin 200mg/m\^2 was administered over 2 hours on day 1 and day 2 of each cycle.
Study NCT00786643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Interferon-1b (IFN-γ)
Description: Gamma-Interferon 150 mcg/m\^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.
Study NCT00786643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.
Study NCT02552459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: sufentanil 150μg， intravenous administration during post-operative 72 hours.
Study NCT02552459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: sufentanil 150μg， intravenous administration during post-operative 72 hours.
Study NCT02552459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 1
Description: dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
Study NCT02552459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 2
Description: dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
Study NCT02552459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 3
Description: dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
Study NCT01807182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study NCT01807182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01807182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01807182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01807182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Tumor Infiltrating Lymphocytes
Description: Undergo TIL infusion
Study NCT01991847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The patients will perform increasing volumes of moderate intensity endurance (e.g. walking, cycling) exercise, leading up to 18 MET-hours per week by the end of three months. Patients will then maintain this activity level for the remaining 9 months, with reduced supervision.
Study NCT00791375 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical activity intervention
Description: Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
Study NCT00791375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
Study NCT02686099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SternaLock 360
Description: Sternal closure with SternaLock 360
Study NCT02686099 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wire Cerclage
Description: Sternal closure with standard wire cerclage
Study NCT00609401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib)
Description: 400 mg bid
Study NCT00609401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 3 MU per 5 day/week for 2 weeks every 4
Study NCT00926081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise training
Description: A standardized supervised exercise training program
Study NCT02999243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV self-testing
Description: The intervention group will be offered HIV self-testing kits for testing HIV status
Study NCT02999243 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Harm reduction education
Description: Both arms will receive harm reduction education
Study NCT02999243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harm reduction education
Description: Both arms will receive harm reduction education
Study NCT02846493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bromocriptine
Description: Patients in this group will receive rectal bromocriptine at a daily dose of 2.5 mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT), Vascular Endothelial Growth Factor(VEGF),drink intake (Intake) and urine volume.
Study NCT02846493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Patients in this group will take oral dexamethasone at a daily dose of 3mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT),Vascular Endothelial Growth Factor(VEGF), drink intake (Intake) and urine volume.
Study NCT01874509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Check Your Drinking
Study NCT01874509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Help Centre
Study NCT04543383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milvexian
Description: Milvexian will be administered orally.
Study NCT04543383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4-Factor Prothrombin Complex Concentrate (4F-PCC)
Description: 4F-PCC will be administered intravenously.
Study NCT04543383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Factor VIIa (rFVIIa)
Description: rFVIIa will be administered intravenously.
Study NCT05302947 — intervention group
Intervention type: DRUG
Intervention: Baricitinib Oral Tablet
Description: Baricitinib was administered at a dose of 4 mg once or twice per day for 3-8 days (5 days on average) depending on the individual patients' condition
Study NCT05302947 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab Injection
Description: Tocilizumab was administered by a single intravenous dose of 400 mg
Study NCT04543383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching to 4F-PCC
Description: Placebo matching to 4F-PCC will be administered intravenously.
Study NCT04543383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching to rFVIIa
Description: Placebo matching to rFVIIa will be administered intravenously.
Study NCT03645148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNeo-Vac-P01
Description: Neoantigen peptides
Study NCT03645148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: immune adjuvant
Study NCT02608736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Half of the participants will receive valproic acid orally for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in placebo arm.
Study NCT02608736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The other half of the participants will receive placebo for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in valproic acid arm.